Seungjean Chai is an Oncology physician affiliated with Levine Cancer Institute. OpenAlex indexes 27 publications with 326 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1021 Morehead Medical Dr
Ste A
Charlotte, NC 282042990
Telephone
980-442-2000Registry record last updated 15 Jul 2024.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Hologic Sales and Service, LLCProgram year20241 payment
- Stemline Therapeutics Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
56.8%Aromatase Inhibitor50.7%Letrozole60%Exemestane27%Anastrozole14%Part D<11 patientsKinase inhibitor6.1%Imatinib Mesylate100%Part D<11 patientsMetabolism & gastrointestinal
18.7%Serotonin-3 Receptor Antagonist12.9%Ondansetron Hcl100%Part D≥16 patientsPotassium supplement5.8%Potassium Chloride100%Part D<11 patientsBlood & clotting
10.8%Factor Xa inhibitor10.8%Eliquis60%Xarelto40%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Financial Toxicity Tumor Board: 5-Year Update on Practice and a Guide to Implementation
Journal of the National Comprehensive Cancer Network
2025 - 80P Tumor immune microenvironment in young, multi-ethnic colorectal cancer patients
Annals of Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”